Graham Capital Management’s MaxCyte MXCT Stock Holding History

Graham Capital Management’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.64K	Sell	10,871 -44,865	-80%	-$41.9K	﹤0.01%	1119
2025 Q4	$86.4K	Buy	55,736 +29,330	+111%	+$46.8K	﹤0.01%	1146
2025 Q3	$41.7K	Buy	+26,406	New	+$45.9K	﹤0.01%	1197
2025 Q2	–	Sell	-36,726	Closed	-$100K	–	1495
2025 Q1	$100K	Buy	36,726 +13,679	+59%	+$53.9K	﹤0.01%	1213
2024 Q4	$95.9K	Buy	+23,047	New	+$87.1K	﹤0.01%	1160

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $88.9M AUM

Graham Capital Management's MXCT Position: Q1 2026 in Review

Graham Capital Management reduced its MaxCyte (MXCT) stake by 80% in Q1 2026, selling an estimated $41.9K and leaving 10,871 shares worth $7.64K. The position accounts for ﹤0.01% of the portfolio, ranked #1119.

Graham Capital Management first reported a position in MXCT in Q4 2024 and has held it in 5 quarters since. The position peaked at $100K in Q1 2025. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

Graham Capital Management held 10,871 shares of MaxCyte worth $7.64K as of Q1 2026.
Graham Capital Management sold 44,865 MaxCyte shares in Q1 2026, an estimated $41.9K.
MaxCyte made up ﹤0.01% of Graham Capital Management's portfolio in Q1 2026, its #1119 holding.
Graham Capital Management first reported a position in MaxCyte in Q4 2024 and has held it in 5 quarters since.
Graham Capital Management's MaxCyte position peaked at $100K in Q1 2025.
130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.